Setting new standards in information exchange for the pharmaceutical and biotech industry
IO360° Speakers, The Whitehead Family, Meet with FDA on a New Treatment for Leukemia
July 13, 2017
Emily Whitehead, 12, joined her parents Tom and Kari Whitehead, on Tuesday in Washington, D.C. at a hearing for the FDA about a new treatment for leukemia. Emily was the first patient to receive this treatment and as you can see in the photo, is doing great. We want to thank the Whiteheads for their relentless advocacy to help get this treatment to patients faster. The Whiteheads spoke at the IO360 conference in NYC.
An FDA panel recommended that the agency approve the first treatment that genetically alters a patient’s own cells to fight leukemia. This treatment powerfully boosts the immune system to shut down the disease.
If the FDA accepts the recommendation, which is likely, the treatment will be the first gene therapy to reach the market. Novartis is in the running to be the first, and it is working on similar types of treatments for another type of leukemia, as well as multiple myeloma and an aggressive brain tumor.
Congratulations to all!
For more info about the IO360 conference, click here.